Browse Articles

Discover research articles across all indexed journals

Feasibility of surgical orchiectomy in prostate cancer patients on long term luteinizing hormone-releasing hormone (LHRH) agonist therapy.

Journal of Clinical Oncology Alon Ya'aqov Lazarovich, Walter Michael Stadler, Scott Eggener et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.265

265 Background: Androgen deprivation, achieved through surgical or medical castration, is central to metastatic prostate cancer (PCa) treatment. Life-long castration is thought to be critical to the management of patients with metastatic disease. Orchiectomy offers an alternative, more convenient, and cheaper alternative for permanent castration, but is under-utilized, in part due to patient reluctance. We hypothesized that patients on long term medical castration therapy would be willing to accept surgical castration as an alternative to repeated LHRH agonist injections. Methods: Men ≥18 years with metastatic PCa, on LHRH agonists for ≥1 year and ≤2 prior systemic therapies, were eligible. Participants first provided consent for an educational session on orchiectomy, followed by the collection of demographic and disease characteristics. Those providing further consent completed the PROMIS sexual function and satisfaction measures v2.0 and the Hopwood body image surveys, with a urology consult offered. At 6 months, patients completed the same surveys, and those undergoing orchiectomy also completed the decision regret scale. 100 patients agreeing to the educational session were required to provide a 10% confidence interval on an estimated 30-50% of patients undergoing an orchiectomy. Results: Of the 130 patients approached, 101 signed the first consent form (education), 58 signed the second (surveys), and 27 agreed to meet with the urology team. Patients agreeing to the educational session had a median age of 71 years (IQR 65-75), 46% were Black and 48% White, 48% completed college or an advanced degree, 36% had annual income > $80K, 58% were married and 64% received systemic therapy other than LHRH agonists. Fourteen patients underwent bilateral orchiectomy (one subcapsular). No association was found between orchiectomy and race, education, annual income, or marital status. While ~75% of all patients were dissatisfied with their sexual life, the vast majority had no body image concerns. Decision regret was low, with 13/14 patients satisfied with their choice of orchiectomy. Pathology revealed testicular atrophy in all cases. Conclusions: Only 11% of patients approached, and 14% of patients who participated in an educational session on orchiectomy proceeded with the procedure, suggesting limited feasibility for surgical castration in patients on long-term LHRH agonists. Testicular atrophy suggests that discontinuing medical castration may be an alternative cost-effective strategy to maintain castration in prostate cancer patients with metastatic disease. Clinical trial information: NCT04705038 .

Trends and demographic disparities in the preferred place of death for bladder cancer patients in the United States (2000–2020): An analysis from the CDC database.

Journal of Clinical Oncology Manas Vaibhav Pustake, Mohammad Arfat Ganiyani, Atulya Aman Khosla et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.747

747 Background: Understanding trends in end-of-life care for bladder cancer patients, particularly their preferred place of death (PPOD), is essential for improving palliative care planning. Despite being a leading cause of mortality in the U.S., there is limited insight into how preferences for end-of-life settings have evolved over time, or how they vary across demographic groups. Identifying these trends can help enhance care quality and address disparities in access to hospice and home-based care. This study aims to provide a comprehensive analysis of PPOD trends for bladder cancer patients from 2000 to 2020. Methods: Data from the CDC WONDER database were used to analyze bladder cancer mortality trends between 2000 and 2020. Deaths were categorized by place of death (home, hospice, medical facility, nursing home), age, race, census region, and year. Descriptive statistics summarized mortality trends, and chi-square tests assessed associations between demographic characteristics and place of death. Logistic regression identified factors associated with hospice utilization, adjusting for age, race, and region. The analysis also examined the impact of the COVID-19 pandemic on end-of-life care in 2020. Results: Between 2000 and 2020, there were 293,906 bladder cancer deaths in the U.S., with the South accounting for the highest proportion (35.6%). Home was the most common place of death (41.6%), followed by medical facilities (24.4%), nursing homes (19.5%), and hospice facilities (9.0%). Significant associations were found between place of death and age, race, and region (p < 0.001). Logistic regression showed younger individuals (under 85) had higher odds of dying in hospice, while Black individuals were less likely to use hospice than White individuals (OR = 0.699, p < 0.001). Hospice utilization increased over time (OR = 1.134 per year, p < 0.001). In 2020, home and hospice deaths increased, with a decline in medical facility deaths, likely due to the COVID-19 pandemic. Conclusions: Hospice care and home-based end-of-life care have become more prominent, though disparities in access persist, particularly among racial and regional groups. These findings highlight the need for more inclusive palliative care strategies to ensure equitable access to compassionate end-of-life care for all patients. Logistic regression results for factors influencing hospice utilization. Variable B S.E. p-value Odds Ratio 35-44 years -18.100 1742.864 0.992 0.000 45-54 years 0.309 0.041 <0.001 1.362 55-64 years 0.291 0.023 <0.001 1.338 65-74 years 0.207 0.018 <0.001 1.230 75-84 years 0.121 0.017 <0.001 1.128 Asian or Pacific Islander -19.165 946.130 0.984 0.000 Black or African American -0.358 0.031 <0.001 0.699 Year (2000-2020) 0.126 0.001 <0.001 1.134

Polarization-insensitive microwave power receiving composite array based on reflection phase gradient metasurfaces

Applied Physics Letters Yi-Zhe Huang, Qiang Yang, Han Xiong et al. Feb 10, 2025 DOI: 10.1063/5.0248205

This paper presents a polarization-insensitive microwave power receiving composite metasurface array. The composite array consists of a reflection phase gradient metasurface array and a horizontal omnidirectional antenna, with a central operating frequency of 5.8 GHz. The reflection phase gradient metasurface array elements are insensitive to the polarization of the incident wave and are arranged radially around the array center. This configuration creates a radial reflection phase gradient that efficiently converts incident plane waves of different polarizations into surface waves converging toward the center. The surface wave energy is then extracted by the horizontal omnidirectional antenna and converted into direct current (DC) by a rectifier. Numerical simulations demonstrate that the composite array maintains effective surface wave excitation and propagation toward the center for both circularly polarized and various horizontally polarized plane waves, achieving a plane wave-to-surface wave conversion efficiency of 74.89%. Experimental validation shows that the proposed array achieves a maximum energy collection efficiency of 62.23% and an RF-DC conversion efficiency of 39.96% over a broad frequency range of 5.6–6.0 GHz. This study achieves polarization insensitivity while simultaneously enhancing the operational efficiency of microwave energy receivers. The results offer a valuable design reference for leveraging reflection phase gradient arrays in wireless power transfer applications.

Addressing imbalanced data classification with Cluster-Based Reduced Noise SMOTE

PLoS ONE Javad Hemmatian, Rassoul Hajizadeh, Fakhroddin Nazari Feb 10, 2025 DOI: 10.1371/journal.pone.0317396

In recent years, the challenge of imbalanced data has become increasingly prominent in machine learning, affecting the performance of classification algorithms. This study proposes a novel data-level oversampling method called Cluster-Based Reduced Noise SMOTE (CRN-SMOTE) to address this issue. CRN-SMOTE combines SMOTE for oversampling minority classes with a novel cluster-based noise reduction technique. In this cluster-based noise reduction approach, it is crucial that samples from each category form one or two clusters, a feature that conventional noise reduction methods do not achieve. The proposed method is evaluated on four imbalanced datasets (ILPD, QSAR, Blood, and Maternal Health Risk) using five metrics: Cohen’s kappa, Matthew’s correlation coefficient (MCC), F1-score, precision, and recall. Results demonstrate that CRN-SMOTE consistently outperformed the state-of-the-art Reduced Noise SMOTE (RN-SMOTE), SMOTE-Tomek Link, and SMOTE-ENN methods across all datasets, with particularly notable improvements observed in the QSAR and Maternal Health Risk datasets, indicating its effectiveness in enhancing imbalanced classification performance. Overall, the experimental findings indicate that CRN-SMOTE outperformed RN-SMOTE in 100% of the cases, achieving average improvements of 6.6% in Kappa, 4.01% in MCC, 1.87% in F1-score, 1.7% in precision, and 2.05% in recall, with setting SMOTE’s neighbors’ number to 5.

Host plant flooding stress in soybeans differentially impacts avirulent and virulent soybean aphid (Aphis glycines) biotypes

Scientific Reports Margaret T. Lewis, Jelmer W. Poelstra, Andrew P. Michel Feb 10, 2025 DOI: 10.1038/s41598-025-87561-z

Defining subgroups of patients with intermediate risk prostate cancer for whom active surveillance is safe.

Journal of Clinical Oncology Ruben Del Castillo, Danny Vesprini, Stanley K Liu et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.393

393 Background: A number of guideline groups recommend active surveillance (AS) for patients with low risk prostate cancer as well as selected patients with intermediate-risk prostate cancer (IRPC) – these groups are not well defined. Our group has previously shown that some patients with IRPC have high rates of progression to advanced disease. The goal of this study was to determine a subset of patients with IRPC where AS is safe. Methods: This single-institution, phase II study enrolled men with low-risk and selected IRPC patients since 1995. Patients were followed with PSA every 3-6 months, DRE every 6 months with repeat systematic biopsies at 1 year and every 3 years. Since 2013, MRI staging was done every 2 years with targeted and systematic biopsies done for new or growing lesions. Patients were followed until death or withdrawn consent. Time to treatment, metastasis-free survival (MFS), cause-specific survival (CSS) and overall survival were calculated from date of registration biopsy. Results: 1409 men were analyzed with a median follow-up of 11.0 years (range 1.2 – 26.4 years). Median age and PSA at registration biopsy were 67 years and 5.03 ng/ml. 86.4%, 11.8% and 1.7% had GG1, GG2 and GG3 disease. 72.9%, 5.8%, 7.3% and 13.6% had low, GG1 favourable IRPC (FIR), GG2 FIR and unfavourable risk ds (UIR). 996 men had at least one repeat biopsy, 768 reclassified, 604 underwent treatment, 166 had biochemical failure, 64 developed metastases and 41 died of prostate cancer. 10 year MFS was 97.4%. Absolute percentage pattern 4/5 (APP4) at baseline had a sensitivity of 36%, specificity of 86% and AUC of 64% with an optimal cutpoint of >0.30 for predicting MFS. Multivariable analysis (MVA) revealed APP4 (HR 2.86) at baseline and at repeat biopsy (vs baseline) of high risk vs UIR (HR 5.61) and high risk vs GG2 FIR (HR 10.4) were independent predictors of MFS. 10 year CSS was 98.5%. MVA revealed APP4 (>0.7, AUC 67%; HR 3.13) and high risk vs UIR (HR 34.4) were independent predictors of CSS. Conclusions: Patients with GG1 prostate cancer and those with GG2 FIR and APP4 < 0.30 appear to have very low risk of metastases and prostate cancer death and are suitable for active surveillance.

Prognostic value of quantitative PSMA-PET parameters during chemotherapy in prostate cancer.

Journal of Clinical Oncology Stephan Skawran, Andrei Gafita, Theo Lorenzini et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.33

33 Background: PSMA-PET/CT is increasingly being used to monitor chemotherapy in prostate cancer and shows promise for predicting outcomes and improving response evaluation. This retrospective study aimed to determine the prognostic value of quantitative tumor burden parameters derived from PSMA-PET/CT for overall survival (OS) during taxane-based chemotherapy. Methods: Databases from 6 institutions were screened for patients who underwent[ 68 Ga]Ga-PSMA11-PET and serum PSA measurements at baseline and within three months after last taxane based chemotherapy dose. Tumor segmentation was performed using DeepPSMA software and PSMA-PET whole-body quantitative parameters were obtained: PSMA-positive tumor volume (PSMA-VOL) and maximum/average standardized uptake value (SUV max , SUV mean ). Univariate Cox-regression analyses by hazard ratio (HR) with 95% confidence interval (CI) were used to evaluate association of whole-body quantitative PSMA parameters and PSA levels with OS. Harrell’s concordance index (C-index) was used to determine prognostic accuracy. Optimal cut points were determined by maximizing the log-rank statistic. Results: A total of 128 patients were included, of whom 62/128 (48%) had castration-sensitive prostate cancer and 66/128 (52%) castration-resistant prostate cancer. At baseline, PSMA-VOL numerically reached the highest prognostic value for OS (C-index: 0.88) followed by PSA (C-index: 0.80, p = 0.85), while the percentage change in PSA levels had the highest prognostic value during treatment (C-index: 0.94) significantly higher than percentage change in PSMA-VOL (C-index: 0.85, p = 0.02), (complete data shown in Table 1). Conclusions: Baseline and post-therapeutic PSMA-PET/CT quantitative parameters are prognostic for OS after taxane-based chemotherapy in prostate cancer. Baseline PSMA-VOL had the highest prognostic value for OS, while changes in PSA levels outperformed changes in quantitative PSMA-PET parameters during treatment. Parameter Cut point HR (95% CI) P-value C-index (95% CI) PSMA vol , baseline > 28 ml 5.59 (2.77 – 11.27) < 0.001 0.88 (0.81 – 0.96) SUV mean , baseline < 13.2 2.00 (0.96 – 4.15) 0.06 0.29 (0.13 – 0.45) SUV max , baseline > 71 2.18 (1.23 – 3.86) 0.007 0.69 (0.57 – 0.82) PSA, baseline > 3.9 ng/ml 3.53 (1.75 – 7.13) < 0.001 0.80 (0.69 – 0.92) PSMA vol , relative change > -21 % 4.48 (2.80 – 7.17) < 0.001 0.85 (0.78 – 0.91) SUV max , relative change > -70 % 2.42 (1.50 – 3.82) < 0.001 0.76 (0.67 – 0.86) SUV mean , relative change > -44 % 5.98 (2.57 – 13.88) < 0.001 0.85 (0.73 – 0.98) PSA, relative change > -97 % 7.03 (3.20 – 15.43) < 0.001 0.94 (0.88 – 0.99)

PSA response to Lu177-PSMA-617 in patients experiencing xerostomia and ocular dryness in metastatic castration resistant prostate cancer.

Journal of Clinical Oncology Rebecca Hassoun, Mark Tann, Justin Sims et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.127

127 Background: Lu177-PSMA-617 (PSMA Lu177) therapy can cause dry mouth and/or eyes, as prostate specific membrane antigen (PSMA) is expressed in salivary and lacrimal glands. We evaluate the PSA response in pts with metastatic castration resistant prostate cancer (mCRPC) receiving PSMA-Lu177 who experienced dry mouth/eyes. Methods: The Indiana University Prostate Cancer database was queried for pts with mCRPC who were treated with PSMA Lu177. Adverse Events were documented throughout the course of treatment. PSA30 and PSA50 response were analyzed among subgroups of patients who had presence/absence of xerostomia and ocular dryness. Comparisons between the groups were based on the Chi Square test, or Fisher’s Exact test, if more appropriate. Results: 144 pts with mCRPC were treated with PSMA Lu177 between November 2022 and October 2024. Included pts received at least 2 doses. Median age was 74 (53, 91). 126 pts had metastatic disease in bone, 80 in pelvic lymph nodes, 27 lungs, 20 liver, and 5 brain. 58 pts had 1 prior ARPI, 86 pts had ≥2 prior ARPI. 28 pts had no prior taxane regimen, 116 had at least 1 prior taxane. 23 pts had prior PARP inhibitor. Median follow-up from start of PSMA Lu177 was 9.77 months (1.38-26.9). 62 (43.1%) pts experienced dry mouth, 15 (10.4%) experienced dry eyes, and 13 (9%) experienced both. 92 (63.9%) pts achieved PSA30 response, and 81 (56.3%) achieved PSA 50 response. Conclusions: Patients with mCRPC treated with PSMA Lu177 who reported dry mouth were more likely to experience PSA responses. Number and % of Pts Achieving PSA30 and PSA50 Response Characteristic (N) PSA30 response, N (%) PSA30 p-value PSA50 response, N (%) PSA50 p-value Dry mouth Present (N=62) Absent (N=82) 49 (79%)43 (52.4%) 0.0010 41 (66.1%)40 (48.8%) 0.0377 Dry eyes Present (N=15) Absent (N=129) 11 (73.3%)81 (62.8%) 0.4211 8 (53.3%)73 (56.6%) 0.8099 Dry eyes and/or dry mouth Present (N=64) Absent (N=80) 51 (79.7%)41 (51.3%) 0.0004 43 (67.2%)38 (47.5%) 0.0180

Relationship of spatial transcriptomic analyses with distance-associated transcriptomic spectrum and morphology-specific signatures of localized prostate cancer.

Journal of Clinical Oncology Brendan Raizenne, Hanbing Song, Nancy Greenland et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.422

422 Background: Current clinical management and classification of prostate cancer is dependent upon specimen morphology assessment. Limited studies have focused on identifying and mapping transcriptomic signatures within morphological variants. Additionally, the impact of transcriptomic distance-relationship between benign and tumor glands has yet to be identified. In this analysis, we profiled and derived signature gene sets for morphological variants and assessed the spatial impact of distance from the adjacent tumor areas on surrounding benign tissues. Methods: Four (three African American and one European ancestry) formalin fixed paraffin embedded prostate cancer samples were obtained via radical prostatectomy and underwent the GeoMx DSP workflow with gene expression level counts. The four patients each had different dominant morphologic features on the slide used, with one patient with extensive foamy gland morphology, one with extensive atrophic morphology, one with extensive mucinous morphology, and one with extensive Gleason pattern 5 carcinoma. Other regions of interest (ROIs) were benign (including benign glands, benign stromal) or mixed tumor/benign. Transcriptomic analysis was performed on these ROIs to derive the morphology-specific gene signatures. Additionally, distance-based spectrum of proximity of benign ROIs to tumor ROIs was constructed to identify genes that are significantly associated with distance to the nearest tumor ROI. Results: 96 ROIs from four patients (denoted by the dominant morphological tumor features) were annotated. In total, 95 ROIs and 8,102 genes passed quality control for analyses. A distance-based spectrum analysis revealed that benign ROIs that are closer to tumor ROIs were highly enriched in transcriptomic androgen signature and MYC signature and endothelial or club-like features were enriched in benign ROIs further from tumor ROIs. Moreover, distinct gene set signatures were established for each morphological feature. Conclusions: Benign ROIs closer to the tumor are more tumor-like and enriched in androgen receptor pathways and MYC signatures. We identified transcriptomic differences among the morphological tumor features that demonstrate inter-patient and intra-patient tumor heterogeneity.

Resonant-type multifunctional device using organic piezoelectrics for detecting differential pressure and acceleration

Applied Physics Letters Yuki Noda, Kunihiro Matsubara, Naomi Toyoshima et al. Feb 10, 2025 DOI: 10.1063/5.0246846

In this study, a multifunctional device was developed using the organic piezoelectric material polyvinylidene fluoride (PVDF) to detect mechanical operations. This device utilizes a mechanism in which the resonance of the element structure is excited and detected using PVDF. This enabled the proposal of a device principle that can allow detection of various physical quantities, such as differential pressure and acceleration. The device can detect low pressures of up to 1.5 kPa with a sensitivity of −0.19 Hz/Pa. Additionally, it can measure acceleration with output linearity and cross-axis sensitivity. This device is advantageous because it can evaluate both pressure and acceleration using a common sensor structure and measurement methods, and it can be manufactured at room temperature using inexpensive materials. It holds potential for applications in the maintenance of various industrial machinery and monitoring of natural disasters.

On the hedge and safe-haven abilities of bitcoin and gold against blue economy and green finance assets during global crises: Evidence from the DCC, ADCC and GO-GARCH models

PLoS ONE Yasmine Snene Manzli, Mohamed Fakhfekh, Azza Béjaoui et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0317735

This paper investigates the diversification, hedging, and safe-haven capabilities of Bitcoin and gold against blue economy and green finance assets using three different MGARCH models (DCC, ADCC, and GO-GARCH) during adverse events such as the COVID-19 health crisis and the 2022 Russia-Ukraine conflict. Blue economy assets, which refer to sectors that sustainably utilize ocean resources, are a key focus alongside green finance assets. The findings reveal that during crises, Bitcoin demonstrates robust safe-haven characteristics, particularly against blue economy assets like BJLE and OCEN. Conversely, gold exhibits pronounced safe-haven properties against specific blue economy and green finance assets such as BJLE and FAN. The GO-GARCH model highlights gold’s strong diversification and safe-haven roles, especially against BJLE. Bitcoin, on the other hand, is more effective as a diversifier for PIO. Moreover, the GO-GARCH model consistently outperforms the DCC and ADCC models in terms of hedging effectiveness, showing that gold is the preferred hedging instrument for GNR and TAN, while Bitcoin is more effective for other blue and green assets. The results underscore the distinct roles of Bitcoin and gold in portfolio management strategies, offering insights for investors navigating market uncertainties in the context of sustainable investments.

Integrated visual and text-based analysis of ophthalmology clinical cases using a large language model

Scientific Reports Vera Sorin, Noa Kapelushnik, Idan Hecht et al. Feb 10, 2025 DOI: 10.1038/s41598-025-88948-8

A phase 2, randomized, open-label study of gemcitabine/cisplatin plus cemiplimab (REGN2810, anti-PD-1) with or without fianlimab (REGN3767, anti-LAG-3) for organ preservation in patients with localized muscle-invasive bladder cancer (NeoSTOP-IT).

Journal of Clinical Oncology Alexander Z Wei, Basil Bakir, Andrew T Lenis et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps882

TPS882 Background: Neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) remains the standard of care for muscle-invasive bladder cancer (MIBC) – a disease with a median diagnosis age of 73 years old. While curative, RC negatively impacts quality of life and conveys significant rates of morbidity (60%) and mortality (5%), highlighting the need for bladder preservation. Several trials have shown the curative potential of NAC (Grossman, NEJM 2003), immunotherapy (Necchi, JCO 2018), and chemoimmunotherapy (Galsky, Nat Med 2023) (Powles, NEJM 2024) in patients with MIBC. LAG-3 is an immune checkpoint receptor that is highly expressed in exhausted tumor-infiltrating lymphocytes within bladder cancer contributing to increased tumor tolerance and a poor overall prognosis. Fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) has been previously shown to be both tolerable and effective in patients with solid tumors. Methods: Neo-STOPIT is a phase 2, open-label, randomized trial with continuous Bayesian toxicity monitoring. Eligible patients must have histologically confirmed MIBC (T2-T3 N0 M0). Mixed histology is permitted if there is a urothelial component. Upper tract disease, prior immunotherapy, and/or bladder chemoradiation is not permitted. Patients will undergo maximal transurethral resection of bladder tumor (TURBT) followed by gemcitabine and cisplatin (21 day cycles). Patients will be randomized 2:1 to receive concomitant cemiplimab (350 mg IV q3w) + fianlimab (1600 mg IV q3w) or cemiplimab. Patients will then repeat TURBT and imaging. Patients with clinical complete response (cCR) may defer RC and continue maintenance immunotherapy for 13 more cycles with surveillance urinary cytology/cystoscopy, imaging, and circulating tumor DNA. Patients without a cCR will undergo RC. The primary endpoint of cCR is defined as the absence of: residual tumor on cystoscopy, metastatic disease on cross-sectional imaging, and positive urine cytology. Secondary endpoints include bladder-intact survival, recurrence free survival, overall survival, and safety/tolerability. Translational exploratory endpoints, including organoid establishment, are planned. We will enroll 36 patients (24 patients in C+F arm). We hypothesize that 70% patients in the C+F arm will achieve cCR compared to 43% (historical control). At least 21 patients will give us 80% power for a one-sided Z-test at a significance of 0.05. To ensure patient safety, toxicity will be monitored using the Bayesian method of Thall et. al. The study will be stopped, at any time during the study, if we observe 70% or more probability that the serious treatment-related adverse event rate is >30%. Recruitment will begin January 2025. Clinical trial information: NCT06571708 .

Prognostic impact of germline deleterious variants and variants of uncertain significance in advanced prostate cancer: A call for functional elucidation.

Journal of Clinical Oncology Maitane Alonso Monasterio, Iñigo Tellaetxe Elorriaga, Ricardo Fernández et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.211

211 Background: Prostate cancer remains the most prevalent solid tumor in men and the third leading cause of cancer-related mortality globally. Tumor aggressiveness and poorer clinical outcomes are associated with certain germline variants. Current technological developments in genetic testing have improved the identification of variants of uncertain significance (VUS), adding complexity to the challenging process of clinical decision-making. The aim of this project was to explore the potential correlation between the identified germline variants and the clinical outcomes in patients with metastatic prostate cancer (mPC). Methods: This retrospective study was conducted at a tertiary care center and included a cohort of 57 patients with mPC who underwent germline genetic testing from January 2021 to December 2022. DNA sequencing was performed by next-generation sequencing (Miniseq, Illumina) using a custom gene panel of 72 genes, and two commercial software packages were employed for variant identification. Variant reanalysis was performed in April 2024. A descriptive and exploratory statistical analysis together with a survival analysis was conducted. Hazard ratios (HRs) with 95% confidence intervals (CIs) estimated with the Cox Proportional Hazards model and p-values for the survival curves obtained by the Kaplan-Meier estimator are presented. Results: A total of 57 patients were included in the analysis, of whom 27/57 (47.5%) had synchronous metastatic disease, while 18/57 (39.1%) had a high-volume tumor (CHAARTED criteria) and 22/57 (47.8%) had high-risk disease (LATITUDE criteria). Of all patients, 19 (33,3%) carried reportable germline variants. Of these, 5 (15.8%) were classified as pathogenic or likely pathogenic, 14 (73.68%) were classified as VUS and in two cases (10.53%) both co-occurred. The impact of the reported variants (including VUS) in homologous recombination repair (HRR) genes ( BRCA1, BRCA2, BARD1, RAD50, RAD51C, RAD51D, PALB2, ATM, CHEK2, NBN ) is summarized in the accompanying table. Conclusions: These results seem to indicate that carrying a VUS in an HRR gene could be associated with worse overall survival. This finding further emphasizes the need to report and elucidate the clinical significance of VUS through precise functional studies. A comprehensive somatic and clinical outcome analysis is ongoing. Survival analysis summary. Germline HRRreportable variants mOS* (months) mOS* (months) N(patients with reportable variants) HR 95% CI p- value Pathogenic/Likely Pathogenic vs. None (including VUS) 53.4 56.3 3 1.27[0.38 – 4.20] 0.86 Only VUS vs. None 40.4 72.0 11** 1.76[0.73 – 4.21] 0.0478 All vs. None 50.3 72.0 14 2.05[0.99 – 4.24] 0.0263 *The diagnosis of metastatic prostate cancer serves as the baseline for OS. **One patient was excluded from analysis for having both pathogenic and VUS HRR variants.

Patient satisfaction with geriatric and functional assessments and referral to frailty-related interventions among older adults presenting to the University of Colorado Urologic Oncology Multidisciplinary Clinic.

Journal of Clinical Oncology Mohamoud Ahmed, Aditya Mantha, Stephanie Lakritz et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps273

TPS273 Background: Geriatric assessments (GA) are valuable tools for determining the functional age of patients and represent the standard of care in evaluating vulnerabilities in older adults with cancer. In oncological treatment, these assessments can help refer patients to appropriate ancillary resources, such as physical therapists, registered dietitians, and social workers, while also assisting in selecting chemotherapy regimens, surgical interventions, and radiation therapy plans. GA and GA-guided management have been shown to positively impact treatment completion and reduce chemotherapy-related toxicity in two recent randomized clinical trials. However, there is minimal data assessing patient satisfaction with the interventions provided through this assessment. This study aims to evaluate patient experiences and acceptance of GA and fragility-based referrals recommended by GA, while also identifying patient-reported barriers to accessing these referred resources. Understanding patient acceptability towards geriatric and functional assessments, along with the determinants and barriers to referral completion, can provide additional information to improve oncologic care for older patients. Methods: This is a single-center feasibility study enrolling patients aged 65 and older who are diagnosed with genitourinary cancer and present to the University of Colorado Urologic Oncology multi-disciplinary conference (MDC). The primary endpoint is the patient-reported acceptability of incorporating geriatric and functional assessments. The secondary endpoint is patient-reported determinants and barriers to completing appropriate referrals based on findings from the GA. Patients will undergo a Practical Geriatric Assessment (PGA) and a Stopping Elderly Accidents, Deaths, and Injuries (STEADi) assessment. Based on their functional score, patients will be referred to Cancer Rehabilitation Medicine, physical therapy, occupational therapy, or the BfitBwell exercise program. Additionally, if the patient’s weight has decreased by more than 3 kilograms in the 3 months prior to their visit, they will be referred for nutritional support. Patients will also be referred to social services if they report significant concerns regarding their ability to manage daily living activities or if they lack adequate social support. Patient acceptability will be collected using validated acceptability of intervention surveys. Semi-structured qualitative interviews will be conducted 8 weeks after the patient’s MDC visit, focusing on patient-reported determinants and barriers to completing fragility-related referrals.

Hypofractionated radiotherapy for prostate cancer (HYDRA): An individual patient data meta-analysis of randomized trials in the MARCAP consortium.

Journal of Clinical Oncology Amar Upadhyaya Kishan, Yilun Sun, David P. Dearnaley et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.385

385 Background: Trials comparing moderately hypofractionated radiotherapy (MHFRT) against conventionally-fractionated radiotherapy (CFRT) for prostate cancer have varied considerably in intent (non-inferiority vs. superiority) and MHFRT dose. Herein, we compare the efficacy and toxicity profiles of isodose MHFRT and dose-escalated MHFRT. Methods: Individual patient data were obtained from 7 phase III trials comparing MHFRT vs. CFRT: three (n=3454) with isodose and four (n=2426) with dose-escalated MHFRT. Meta-analyses were designed to compare progression-free survival (PFS), late grade ≥2 genitourinary (GU) and late grade ≥2 gastrointestinal (GI) physician-scored toxicity, and clinically-significant decrements in patient-reported urinary or bowel quality of life (QOL). Results: After a median follow-up of 5.4 years (interquartile range [IQR], 4.6-7.2) and 7.1 years (IQR 5.7-8.4) following isodose and dose-escalated MHFRT, there were no differences in PFS (hazard ratio [HR] 0.92, 95%CI 0.81-1.05 and HR 0.94, 95%CI 0.82-1.09, respectively). Neither isodose nor dose-escalated MHFRT were associated with increased odds of grade ≥2 GU toxicity (odds ratio [OR] 1.16 95CI% 0.86-1.57 and OR 1.20, 95%CI 0.95-1.51). The odds of grade ≥2 GI toxicity were higher with dose-escalated (OR 1.48, 95%CI 1.14-1.92) but not isodose MHFRT (OR 1.30, 95% 0.59-2.87). Isodose MHFRT did not show different odds of urinary (OR 1.03, 95%CI 0.51-2.09) and bowel (OR 0.76, 95%CI 0.40-1.43) QOL decrements, while dose-escalated MHFRT was associated with greater odds of bowel (OR 1.68, 95%CI 1.07-2.61), but not urinary (OR 1.57, 95%CI 0.87-2.85), QOL decrement. Conclusions: Isodose MHFRT and dose-escalated MHFRT both have similar efficacy compared with CFRT, but dose-escalated MHFRT is associated with higher physician-scored and patient-reported bowel and urinary toxicity. Isodose regimens, e.g. 60 Gy in 20 fractions, should be the standard MHFRT regimen for localized prostate cancer.

High thermal durability and thermoelectric performance with ultra-low thermal conductivity in <i>n</i>-type single-walled carbon nanotube films by controlling dopant concentration with cationic surfactant

Applied Physics Letters Hisatoshi Yamamoto, Takuya Amezawa, Yutaro Okano et al. Feb 10, 2025 DOI: 10.1063/5.0252016

Single-walled carbon nanotubes (SWCNTs) are promising candidates for use in thermoelectric generators (TEGs) to power Internet of Things (IoT) sensors. For practical applications, the major challenge for SWCNTs is improving the thermoelectric performance and thermal durability of n-type SWCNT films. Here, SWCNT inks were prepared using a dopant, which is a cationic surfactant of dimethyldioctadecylammonium chloride (DODMAC), by changing the mass ratio of DODMAC/SWCNT. The SWCNT films were fabricated by vacuum filtering, followed by heat treatment at 423 K. The in-plane thermoelectric properties were measured at 300 K, and the Seebeck coefficient changed from positive to negative values when the DODMAC/SWCNT was 10−2. The highest dimensionless figure-of-merit, ZT, of 1.0 × 10−2 was exhibited at a DODMAC/SWCNT of 80, which was close to saturation concentration. This ZT was achieved mainly because the thermal conductivity decreased significantly to 0.16 W/(m · K), and it is currently one of the highest values among those of n-type SWCNT films with various dopants. To demonstrate power generation, we fabricated a SWCNT-TEG consisting of n-type SWCNT films with the highest ZT. The SWCNT-TEG exhibited an output voltage of 24 mV and a maximum power of 0.9 μW at a temperature difference of 80 K. Furthermore, to investigate the thermal durability of n-type SWCNT films, thermal cycling tests were performed at temperatures ranging from 300 to 423 K. The SWCNT film with a DODMAC/SWCNT of 80 exhibited the highest durability. These findings will contribute to the widespread use of SWCNT-TEGs as power sources for IoT sensors.

Blueprint for progress: Understanding the driving forces of BIM adoption in Kingdom of Saudi Arabia (KSA) construction industry

PLoS ONE Muzaffar Iqbal, Irfan Ullah, Heba Abdou et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0313135

Building information modeling (BIM) as a virtual and digital mode of representing construction activities gained significant attention and facilitated construction projects. Nevertheless, many driving forces (DFs) trigger the adoption of BIM. Different kinds of studies have been conducted regarding the DFs of BIM adoption in developed countries. However, few studies have classified the adoption of DFs of BIM technology in developing countries such as the Kingdom of Saudi Arabia (KSA). A range of previous literature identified these DFs in a different context, but there is a need to answer two main questions. First, what DFs could influence BIM adoption in the construction sector of (KSA); second, what could be the possible framework to prioritize these DFs. Therefore, Fuzzy Delphi Methodology (FDM), Interpretive structural modeling (ISM), and MICMAC were applied to answer these questions. Study results highlight that ’Reduced cycle time of the design process’ and ’Efficient construction planning and management’, are the main DFs to BIM adoption in the construction sector of (KSA). This study is the first to employ a hybrid FDM, ISM, and MICMAC approach to evaluate BIM implementation DFs in the KSA context. This study informs policymakers and industry practitioners in (KSA) to develop targeted strategies for effective BIM adoption. This study enhances collaboration and communication among construction industry stakeholders by understanding the significant DFs and their interrelationships.

Analysis of antibacterial drug use and bacterial resistance in psychiatric hospital in the epidemic

Scientific Reports Ying Jiang, Rongrong Lu, Yuan Shen et al. Feb 10, 2025 DOI: 10.1038/s41598-025-88260-5

Characterizing the immune effects of enfortumab vedotin (EV) on peripheral blood mononuclear cells (PBMCs) in metastatic urothelial cancer patients (mUC).

Journal of Clinical Oncology Aditi Gupta, Carlo Sevilla, Nicole Loren Pihlstrom et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.833

833 Background: EV has high antitumor activity and improved survival in advanced urothelial cancer both as a single agent and in combination with pembrolizumab. We hypothesized that EV primes a systemic immune response for effective T cell mediated killing. Methods: We conducted a retrospective analysis of mUC patients treated with EV at Memorial Sloan Kettering Cancer Center to evaluate its impact on peripheral blood immune cells. PBMCs were isolated from 32 patients with mUC on C1D1 and C2D1 of EV monotherapy. A 32-color spectral flow cytometry panel was used to identify T-cell subsets, and their correlation with treatment response using Wilcoxon rank sum test. Response was determined by an independent radiologist’s assessment of the first on-treatment scan according to RECIST v1.1 criteria. Results: Of 32 patients, 75% were men with median age 73. 81.3% received prior platinum-based chemotherapy and 93.8% received prior PD-1/PD-L1 immunotherapy. Partial response (PR) was observed in 16 patients, while 16 had stable disease (SD) or progressive disease (PD). At C1D1, CD8+ T cell frequencies did not correlate with response; however, a reduction in circulating CD8+ T cells at C2D1 correlated with poor response (SD + PD, p &lt; 0.05). At baseline, high frequency of CD8+PD-1+ T cells correlated with poor response (p &lt; 0.05). Baseline high frequencies of CD8+PD-1+LAG3+ and CD8+PD-1-LAG3+ T cells were also associated with poor response (p &lt; 0.05). At C2D1, high frequency of CD8+TIM3+ (p &lt; 0.05) and CD8+LAG3+ (p &lt; 0.05) T cells correlated with non-response. Additional activation markers on CD8+ T cells at C1D1 were analyzed (Table). Within the memory CD8+ and CD4+ T cell compartments, patients with higher circulating naïve memory cells (CD45RA+CCR7+) at baseline were less likely to respond to EV (p &lt; 0.05), while those with higher frequencies of T effector memory (CD45RA-CCR7-) and effector T cells (CD45RA+CCR7-) were more likely to respond to EV (p &lt; 0.05). No significant correlations were found between memory T cells and response at C2D1. Conclusions: At baseline and on treatment, distinct immunophenotypes are detected in the peripheral blood of EV treated patients, potentially correlating with treatment response. Ongoing studies aim to further elucidate the influence of prior anti-PD-1/PD-L1 therapy and the combination of EV with pembrolizumab on these immunophenotypic profiles. Peripheral T cell phenotypes at C1D1 from mUC patients treated with EV. Peripheral Immune Cell at C1D1 Responders (PR, %CD45+) Non-Responders (SD + PD, %CD45+) p-value CD8+ 11.1 13.7 0.10 CD8+ Fold Change (C1D1/ C2D1) 1.07 0.74 0.04 Responders (PR, %CD8+) Non-Responders (SD + PD, %CD8+) p-value CD8+ ICOS+ 37.6 56.5 0.01 CD8+ PD1+ 40.9 64 0.04 CD8+ TIGIT+ 39.9 54.6 0.01 CD8+ LAG3+ 1.16 1.23 0.67 CD8+ TIM3+ 23.6 18.5 0.04